Coastal Bridge Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Coastal Bridge Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$447K	Buy	55,838 +108	+0.2%	+$929	0.03%	338
2026 Q1	$448K	Buy	55,730 +1,900	+4%	+$18.2K	0.03%	328
2025 Q4	$627K	Sell	53,830 -37,845	-41%	-$368K	0.05%	279
2025 Q3	$921K	Buy	91,675 +4,650	+5%	+$66.7K	0.07%	218
2025 Q2	$1.52M	Buy	87,025 +40,275	+86%	+$581K	0.13%	164
2025 Q1	$588K	Buy	+46,750	New	+$562K	0.05%	264

Other funds holding SPRY

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Coastal Bridge Advisors's SPRY Position: Q2 2026 in Review

Coastal Bridge Advisors increased its ARS Pharmaceuticals (SPRY) stake by 0.19% in Q2 2026, buying an estimated $929 and bringing the position to 55,838 shares worth $447K. The position accounts for 0.03% of the portfolio, ranked #338.

Coastal Bridge Advisors first reported a position in SPRY in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.52M in Q2 2025. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

Coastal Bridge Advisors held 55,838 shares of ARS Pharmaceuticals worth $447K as of Q2 2026.
Coastal Bridge Advisors bought 108 ARS Pharmaceuticals shares in Q2 2026, an estimated $929.
ARS Pharmaceuticals made up 0.03% of Coastal Bridge Advisors's portfolio in Q2 2026, its #338 holding.
Coastal Bridge Advisors first reported a position in ARS Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Coastal Bridge Advisors's ARS Pharmaceuticals position peaked at $1.52M in Q2 2025.
208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Coastal Bridge Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.